Lytix Q2 2024: Verrica’s Phase II Data Changes the Case - Redeye

Redeye comments on Lytix’ second quarter report 2024. Strong phase II data were presented by Verrica in August. This changes the investment case somewhat, putting basal cell carcinoma on an equal footing with melanoma.

Länk till analysen i sin helhet: https://www.redeye.se/research/1036610/lytix-q2-2024-verricas-phase-ii-data-changes-the-case?utm_source=finwire&utm_medium=RSS